[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
December 10, 2008

Contaminated Heparin Seized by FDA

JAMA. 2008;300(22):2597. doi:10.1001/jama.2008.786

The US Food and Drug Administration (FDA) sent federal marshals to Celsus Laboratories Inc in Cincinnati on November 6 to seize the remains of 11 lots of contaminated heparin after the agency felt the company failed to take sufficient action to recall the products (http://www.fda.gov/bbs/topics/NEWS/2008/NEW01912.html).

Celsus said it had identified and quarantined suspect heparin batches following a March 6 disclosure from the FDA to the public of the potential presence of contaminated heparin imported from China containing oversulfated chondroitin sulfate (OSCS), a substance that mimics heparin's anticoagulant activity. The company said customers who had received heparin from suspect batches were informed in late March and early April (http://www.celsuslaboratories.com/news.php).